TNFRSF10B and cancer: Previously,we have shown that the topoisomerase I inhibitor CPT inhibits FLIPexpression in human cancer cells, and this underpins the synergy observedbetween CPT and human anti-DR5 agonists., Here, we confirmed that this relationship was maintained in murineMC38 and 3LL cancer cells, where treatment with CPT concentrationsof 0.1 μg/mL or higher led to downregulation of FLIP (Figure A and 3B).